Cardiovascular morbidity and mortality after orthotopic liver transplantation
Top Cited Papers
- 1 March 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (6) , 901-906
- https://doi.org/10.1097/00007890-200203270-00012
Abstract
Hyperlipidemia and hypertension have been reported in liver allograft recipients and contribute to an increased risk of ischemic heart disease (IHD) after orthotopic liver transplantation (OLT). The aims of the study were (1) to determine the prevalence of risk factors for IHD in these patients and (2) to compare the observed incidence of cardiovascular events and related mortality in allograft recipients with a matched population. One hundred ten consecutive adults (50 male) who attended for review after OLT (median follow-up 3.9 years; range 0.1–17.9) were assessed for cardiovascular risk factors using current blood pressure, diabetic status, and smoking history and measurements of total cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations. Cardiovascular events and cardiovascular mortality data were collected from the prospective database of all adult liver allograft recipients and compared to matched data from myocardial infarction registries and Office for National Statistics data, respectively. Raised serum cholesterol (>5.0 mmol/L) was found in 48 (44%) patients (18 male), and systolic hypertension (>140 mmHg) was found in 69 (63%) patients (27 male). The relative risk of ischemic cardiac events was 3.07 (95% [confidence interval] CI, 1.98–4.53) and the relative risk for cardiovascular deaths was 2.56 (95% CI, 1.52–4.05) in allograft recipients compared to an age-matched population without transplants. Liver allograft recipients have a greater risk of cardiovascular deaths and ischemic events than an age- and sex-matched population. The prevalence of raised cholesterol concentrations in patients after OLT is similar to those in previous reports. Moderate hypertension and hyperlipidemia may be more detrimental in patients after OLT compared to non-transplant patients without these risk factors.Keywords
This publication has 28 references indexed in Scilit:
- Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapyLiver Transplantation and Surgery, 1999
- AGE AND LIVER TRANSPLANTATIONTransplantation, 1998
- Lipid abnormalities in stable liver transplant recipients – effects of cyclosporin, tacrolimus, and steroidsTransplant International, 1998
- TREATMENT OF CYCLOSPORINE-RELATED ADVERSE EFFECTS BY CONVERSION TO TACROLIMUS AFTER LIVER TRANSPLANTATIONTransplantation, 1997
- Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)Liver Transplantation and Surgery, 1997
- A RANDOMIZED PROSPECTIVE TRIAL OF STEROID WITHDRAWAL AFTER LIVER TRANSPLANTATION1,2Transplantation, 1995
- Corticosteroid withdrawal after liver transplantationSurgery, 1995
- Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patientsThe Lancet, 1995
- THE EFFECT OF FK506 VERSUS CYCLOSPORINE ON GLUCOSE AND LIPID METABOLISM—A RANDOMIZED TRIALTransplantation, 1994
- A follow up of 53 adult patients alive beyond 2 years following liver transplantationJournal of Gastroenterology and Hepatology, 1993